Humacyte annual stock-based compensation
2020
2021
2022
2023
2024
2025
Humacyte Stock-Based Compensation Growth & History (HUMA)
Humacyte's stock-based compensation was $9.8M for fiscal 2025.
View full Humacyte company overviewHumacyte annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $9.8M | $3.6M | +58.92% |
| 2024 | 2024-12-31 | $6.1M | −$691,000 | −10.12% |
| 2023 | 2023-12-31 | $6.8M | $644,000 | +10.41% |
| 2022 | 2022-12-31 | $6.2M | −$4.0M | −39.05% |
| 2021 | 2021-12-31 | $10.1M | $5.5M | +116.15% |
| 2020 | 2020-12-31 | $4.7M | — | — |
Humacyte quarterly stock-based compensation
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.6M | $273,000 | +11.69% |
| Q1 2026 | 2026-03-31 | $3.2M | $683,000 | +27.46% |
| Q4 2025 | 2025-12-31 | $2.5M | $776,000 | +45.81% |
| Q3 2025 | 2025-09-30 | $2.5M | $909,000 | +58.57% |
| Q2 2025 | 2025-06-30 | $2.3M | $898,000 | +62.49% |
| Q1 2025 | 2025-03-31 | $2.5M | $1.0M | +71.05% |
| Q4 2024 | 2024-12-31 | $1.7M | $288,000 | +20.48% |
| Q3 2024 | 2024-09-30 | $1.6M | −$220,000 | −12.42% |
| Q2 2024 | 2024-06-30 | $1.4M | −$404,000 | −21.94% |
| Q1 2024 | 2024-03-31 | $1.5M | −$355,000 | −19.62% |
| Q4 2023 | 2023-12-31 | $1.4M | −$264,000 | −15.81% |
| Q3 2023 | 2023-09-30 | $1.8M | $296,000 | +20.05% |
| Q2 2023 | 2023-06-30 | $1.8M | $350,000 | +23.47% |
| Q1 2023 | 2023-03-31 | $1.8M | $262,000 | +16.94% |
| Q4 2022 | 2022-12-31 | $1.7M | −$1.1M | −40.59% |
| Q3 2022 | 2022-09-30 | $1.5M | −$401,000 | −21.36% |
| Q2 2022 | 2022-06-30 | $1.5M | −$1.4M | −49.11% |
| Q1 2022 | 2022-03-31 | $1.5M | −$981,000 | −38.81% |
| Q4 2021 | 2021-12-31 | $2.8M | — | — |
| Q3 2021 | 2021-09-30 | $1.9M | $707,000 | +60.43% |
| Q2 2021 | 2021-06-30 | $2.9M | — | — |
| Q1 2021 | 2021-03-31 | $2.5M | — | — |
| Q3 2020 | 2020-09-30 | $1.2M | — | — |
Humacyte stock-based compensation trends
Over the last five fiscal years, Humacyte's stock-based compensation increased from $4.7M to $9.8M, a change of $5.1M. The latest reported quarter, Q2 2026, shows $2.6M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Humacyte source filings ↗